Eterna Therapeutics Inc (ERNA)

Nov 16, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World

Nov 16, 2024

Nov 15, 2024

ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India

Nov 15, 2024

Nov 14, 2024

Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com

Nov 14, 2024

Nov 14, 2024

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times

Nov 14, 2024

Nov 14, 2024

Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat

Nov 14, 2024

Nov 05, 2024

Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com

Nov 05, 2024

Nov 05, 2024

Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK

Nov 05, 2024

Oct 30, 2024

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire

Oct 30, 2024

Oct 29, 2024

Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Eterna Therapeutics announces share issuance and executive agreements - Investing.com India

Oct 29, 2024

Oct 29, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Oct 29, 2024

Oct 18, 2024

Eterna, Factor announce license, collaboration agreement - Yahoo Finance

Oct 18, 2024

Oct 18, 2024

Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - BioSpace

Oct 18, 2024

Oct 17, 2024

Eterna secures exclusive license for cell therapy tech - Investing.com India

Oct 17, 2024

Oct 17, 2024

Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK

Oct 17, 2024

Oct 17, 2024

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire

Oct 17, 2024

Oct 06, 2024

Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com

Oct 06, 2024

Oct 01, 2024

Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World

Oct 01, 2024

Sep 27, 2024

Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com

Sep 27, 2024

Sep 27, 2024

Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks

Sep 27, 2024

Sep 27, 2024

Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Sep 27, 2024

Sep 23, 2024

Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

Sep 23, 2024

Sep 23, 2024

Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com

Sep 23, 2024

Sep 23, 2024

Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com

Sep 23, 2024

Sep 11, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World

Sep 11, 2024

Sep 03, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat

Sep 03, 2024

Aug 26, 2024

StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Aug 26, 2024

Aug 22, 2024

Eterna Therapeutics (NASDAQ:ERNA) Shares Up 2.4% - Defense World

Aug 22, 2024

Aug 20, 2024

Eterna Therapeutics sets September 27 for annual meeting By Investing.com - Investing.com Australia

Aug 20, 2024

Aug 19, 2024

Eterna Therapeutics sets September 27 for annual meeting - Investing.com

Aug 19, 2024

Aug 14, 2024

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024 - MSN

Aug 14, 2024

Aug 13, 2024

Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Aug 13, 2024

Aug 05, 2024

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewswire

Aug 05, 2024

Aug 02, 2024

Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update - Defense World

Aug 02, 2024

Aug 02, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World

Aug 02, 2024

Jul 09, 2024

Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at StockNews.com - Defense World

Jul 09, 2024

Jun 30, 2024

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics - Quantisnow

Jun 30, 2024

Jun 30, 2024

Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared ... - Quantisnow

Jun 30, 2024

Jun 30, 2024

Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index - Quantisnow

Jun 30, 2024

Jun 30, 2024

Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Quantisnow

Jun 30, 2024

Jun 30, 2024

Brooklyn ImmunoTherapeutics Reports Inducement Grants - Quantisnow

Jun 30, 2024

Jun 30, 2024

Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement - Quantisnow

Jun 30, 2024

Jun 24, 2024

StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Jun 24, 2024